Core Viewpoint - China Resources Beer (00291) reported a revenue of RMB 37.985 billion for 2025, reflecting a 2% year-on-year decline [1][2] - Adjusted EBITDA reached RMB 9.879 billion, marking a 10% year-on-year increase [1][2] Group 1: Sales Performance - In the second half of 2025, beer sales increased by 0.4%, while the average selling price decreased by 5%, primarily due to proactive promotional activities [1][5] - Management noted positive effects from these promotions, with sales volume and average price both recording growth in the first two months of the year [1][5] Group 2: Management Outlook - The management remains cautiously optimistic about the upcoming peak season [1][5] - For the liquor business, it is anticipated that if operations stabilize, the goodwill impairment losses will narrow this year [1][5] Group 3: Investment Rating - The firm maintains a "Buy" rating, with the target price adjusted from HKD 33.8 to HKD 30.3, which corresponds to an estimated enterprise value to EBITDA ratio of 6.3 times for this year [1][5]

智通财经APP讯，宝胜国际(03813)发布公告，于2026年3月24日注销1066.5万股已回购股份。 ...

截至2026年3月24日收盘，碧桂园（02007）报收于0.32元，较前一交易日上涨5.0%，该股当日开盘0.32 元，最高0.32元，最低0.3元，成交额达8449.77万元。近52周最高0.72元，最低0.25元。 《内幕消息 盈利预告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 碧桂園控股有限公司于近日发布内幕消息公告，披露截至2025年12月31日止年度的盈利预告。公告显 示，董事会预计本集团将实现利润介乎约人民币10亿元至人民币22亿元，对比截至2024年12月31日止年 度的损失约人民币351.45亿元，预期转亏为盈。该盈利主要由于本集团完成债务重组所录得的非现金收 益所致。若撇除债务重组收益的影响，本集团仍录得亏损，主要原因包括行业整体压力导致开发业务毛 利下降，以及对若干资产及物业项目计提减值准备。上述资料基于管理层对未经审核管理账目的初步评 估，尚未经核数师或审核委员会审核。预计本公司将于2026年3月下旬刊发截至2025年12月31日止年度 的正式业绩公告。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《暂停办理股份过户登记手续及关于代扣代缴非居民企业2025年度末期股息的企业所得税》 《截至二零二五年十二月三十一日止年度之末期股息》 最新公告列表 截至2026年3月24日收盘，中国电力（02380）报收于3.22元，较前一交易日上涨1.9%，该股当日开盘 3.2元，最高3.24元，最低3.16元，成交额达4172.08万元。近52周最高3.53元，最低2.58元。 近日，中国电力国际发展有限公司（股份代号：02380）发布截至二零二五年十二月三十一日止年度之 末期股息公告。公告显示，公司宣派末期股息为每股人民币0.168元，相当于每股港币0.1911元（汇率： 1人民币=1.1375港币）。该股息为普通股息，财政年末及宣派报告期末均为2025年12月31日。股东批准 日期为2026年6月8日。除净日为2026年6月10日，递交股份过户文件的最后时限为2026年6月11日 16:30。公司将于2026年6月12日至6月16日暂停办理股份过户登记手续，记录日期为2026年6月16日，股 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1 - The core viewpoint of the article is that Shenzhou Holdings (00861.HK) expects to turn a profit for the fiscal year ending December 31, 2025, with profits projected between RMB 20 million and RMB 40 million, compared to a loss of approximately RMB 254 million in 2024 [1] Group 2 - The anticipated profit growth is primarily attributed to two factors: (1) In 2024, the company achieved operating revenue of RMB 16.657 billion, and it expects significant revenue growth in 2025 due to increased business volume [1] - (2) In 2024, the company recorded an impairment of RMB 365 million on goodwill due to underperformance of its invested subsidiaries, and the expected impairment losses will significantly decrease in 2025 [1]

Core Viewpoint - China Jinmao (0817.HK) reported a significant reduction in average financing costs to 2.75% for the year 2025, indicating a strong financial position and competitive advantage in the industry [1] Financing Costs - The average financing cost decreased significantly compared to the end of 2024, maintaining a low level within the industry [1] - The proportion of low-cost development and operational loans increased to approximately 50% of the total debt structure [1] Debt Structure - The company's debt structure has been further optimized, with a continuous decline in the proportion of foreign currency debt to 20% [1] - Financial safety has been enhanced due to the improved debt structure [1] Liquidity Position - As of the reporting period, the company had over 70 billion yuan in unused bank credit, indicating a strong liquidity position and ample funding reserves [1]

Core Viewpoint - The company expects to turn a profit for the fiscal year ending December 31, 2025, with profits projected between RMB 20 million and RMB 40 million, a significant recovery from a loss of approximately RMB 254 million for the fiscal year ending December 31, 2024 [1] Group 1: Profit Expectations - The company anticipates a profit turnaround due to increased business volume leading to significant revenue growth in 2025 [1] - The projected revenue for 2024 is RMB 16.657 billion, with expectations of further growth in 2025 [1] Group 2: Impairment Losses - In 2024, the company recorded an impairment loss of RMB 365 million on goodwill due to underperformance of its invested subsidiaries [1] - The expected impairment losses are anticipated to decrease significantly in 2025 [1]

Core Viewpoint - A recent issue reported by some Android users regarding the Meituan app involved unexpected deletion notifications for images and videos, which has been attributed to a conflict with third-party SDKs during automatic cache cleaning on certain devices [1] Group 1 - Meituan's official customer service stated that approximately 180 users have inquired about the issue, with potential affected users numbering in the hundreds [1] - The problem has been identified as a local system-level issue on users' devices, and Meituan's app does not read, store, or transfer any personal user data [1] - The vulnerability has been urgently fixed, ensuring that user privacy and account information remain unaffected [1]

Core Viewpoint - China Biopharmaceutical (01177) has achieved an upgrade in its MSCI ESG rating from A to AA, reflecting its leadership in ESG practices among global pharmaceutical companies [2]. Group 1: Stock Performance - As of March 24, 2026, China Biopharmaceutical's stock closed at 5.84 yuan, up 2.1% from the previous trading day [1]. - The stock opened at 5.78 yuan, reached a high of 5.87 yuan, and a low of 5.78 yuan, with a trading volume of 1.56 billion yuan [1]. - The stock has a 52-week high of 9.12 yuan and a low of 3.14 yuan [1]. Group 2: ESG Rating and Practices - The upgrade to AA in the MSCI ESG rating indicates high recognition of the company's management systems and practices in environmental, social, and governance areas [2]. - The company implements a "CARE" core strategy focusing on disease treatment, pharmaceutical accessibility, win-win relationships, and environmental friendliness [2]. - In terms of environmental efforts, the company has reduced major pollutant emission intensity by over 10% annually for five consecutive years and aims for a dual decrease in total carbon emissions and intensity by 2025 [2]. - Three subsidiaries have been awarded national "Green Factory" status [2]. Group 3: Social Responsibility and Innovation - Over the past three years, the company has invested more than 13 billion yuan in R&D, serving over 160 million patients with its key products [2]. - The company has strengthened its innovation pipeline through acquisitions of companies like Lixin Pharmaceutical and Hegia, and has established a global partnership with Sanofi for the exclusive licensing of Rovafexin [2]. - The company has donated over 150 million yuan in the last three years, actively participating in disaster relief, rural revitalization, and inclusive healthcare initiatives [2].